Artwork

Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

03_03 Metastatic Melanoma

36:20
 
Del
 

Manage episode 362882606 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. Patterns of recurrence and approach to stage IV disease
2. Immunotherapy and BRAF/MEK considerations
3. Cross trial comparisons
4. Later line and emerging therapies for advanced melanoma

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Atkins MB et al. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763

2. Robert C et al. NEJM. 2019;381(7):626-636. doi:10.1056/NEJMOA1904059/

3. Lebbé C et al. J Clin Oncol. 2019;37(11):867-875. doi:10.1200/JCO.18.01998

4. Wolchok JD et al. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229

5. Larkin J et al. NEJM. 2015;373(1):23-34. doi:10.1056/NEJMOA1504030

6. Nathan P et al. NEJM. 2021;385(13):1196-1206. doi:10.1056/NEJMOA2103485

7. Sarnaik AA et al. J Clin Oncol. 2021;39(24):2656-2666. doi:10.1200/JCO.21.00612

8. Tawbi HA et al. NEJM. 2022;386(1):24-34. doi:10.1056/NEJMOA2109970

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

42 episoder

Artwork
iconDel
 
Manage episode 362882606 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. Patterns of recurrence and approach to stage IV disease
2. Immunotherapy and BRAF/MEK considerations
3. Cross trial comparisons
4. Later line and emerging therapies for advanced melanoma

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Atkins MB et al. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763

2. Robert C et al. NEJM. 2019;381(7):626-636. doi:10.1056/NEJMOA1904059/

3. Lebbé C et al. J Clin Oncol. 2019;37(11):867-875. doi:10.1200/JCO.18.01998

4. Wolchok JD et al. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229

5. Larkin J et al. NEJM. 2015;373(1):23-34. doi:10.1056/NEJMOA1504030

6. Nathan P et al. NEJM. 2021;385(13):1196-1206. doi:10.1056/NEJMOA2103485

7. Sarnaik AA et al. J Clin Oncol. 2021;39(24):2656-2666. doi:10.1200/JCO.21.00612

8. Tawbi HA et al. NEJM. 2022;386(1):24-34. doi:10.1056/NEJMOA2109970

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

42 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett